MedTrace Logo

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2022-06-14

No results posted yet for this study

Summary

This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp

Conditions

  • Insulin Sensitivity

Interventions

DEVICE

24h Continuous glucose monitoring and urinary C-peptide collection

Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).

Sponsors & Collaborators

  • Pennington Biomedical Research Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2022-02-21
Completion
2022-02-21
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04774081 on ClinicalTrials.gov